Topic
Xanthone
About: Xanthone is a research topic. Over the lifetime, 1639 publications have been published within this topic receiving 25870 citations. The topic is also known as: 9-oxo-xanthene & Diphenyline ketone oxide.
Papers published on a yearly basis
Papers
More filters
TL;DR: A variety of the title compounds is efficiently obtained by one-pot reaction of phenol compounds and salicylic acid/thiosalicylic acids as discussed by the authors, and they can be obtained by a variety of methods.
Abstract: A variety of the title compounds is efficiently obtained by one-pot reaction of phenol compounds and salicylic acid/thiosalicylic acid.
1 citations
Patent•
09 Jun 2010
TL;DR: In this article, the use of the xanthone compounds in induction of the apoptosis of tumor cells, anti angiogenesis and antimetastasis and other aspects were discussed.
Abstract: The invention relates to anticancer active xanthones and a preparation method thereof and a medicinal composition containing the compounds or pharmaceutically acceptable salts thereof. The invention also relates to the use of the xanthone compounds in induction of the apoptosis of tumor cells, anti angiogenesis and antimetastasis and other aspects.
1 citations
Patent•
05 Sep 1973TL;DR: In this paper, a tetrazolyl group in one ring and further substituted in the other ring, optionally for the acridones have antiallergic activity, and xanthone compounds have anti-allergic properties.
Abstract: Acridone and xanthone compounds substituted by at least one tetrazolyl group in one ring, and further substituted in the other ring, optionally for the acridones have antiallergic activity.
1 citations
TL;DR: In this article, a series of xanthone derivatives were synthesized by rhodium-catalyzed cycloaddition and sequential oxidation and the derivatives synthesized for excellent yields, including electron-withdrawing and electron-donating substituents, demonstrated the wide applicability of the proposed approach.
1 citations
TL;DR: It can be concluded that trihydroxyxanthone compounds 4 and 8 with chloro and sulfonate substitution are very potential to be developed as drug agents for Covid-19 disease therapy through protease inhibition.
Abstract: Covid-19 has caused more than 14 million confirmed cases and more than 6 hundred deaths as of 21 July 2020 globally. However, there is no approved drug to treat the disease. Xanthone is a potential therapeutic option for the virus that have been tested using molecular docking. There were 12 of xanthone compounds and its derivatives which have been docked against two protein crystals, 2GX4.pdb and 6FV1.pdb, which obtained two potential compounds of hydroxyxanthone derivatives with sulfonate and chloro substitution. These compounds are potentially developed into one of the agents for the treatment of infection COVID-19 disease. Based on energy data and interactions with amino acid residues when compared with its own native ligands, namely NOL and E8E, respectively. Energy docking and energy docking interactions are equal to - 43.3057and - 45.5805 Kcal/mol respectively, during interactions with amino acid residues in the form of Gly 142, His 163, Cys144, Glu166, Gln164 and His 41. Based on these two data, it can be concluded that trihydroxyxanthone compounds 4 and 8 with chloro and sulfonate substitution are very potential to be developed as drug agents for Covid-19 disease therapy through protease inhibition.
1 citations